Neuroscience Bulletin

, Volume 34, Issue 3, pp 543–545 | Cite as

Cystatin C Induces Insulin Resistance in Hippocampal Neurons and Promotes Cognitive Dysfunction in Rodents

  • Lan Luo
  • Jinyu Ma
  • Yue Li
  • Zongkang Hu
  • Chengfeng Jiang
  • Hao Cai
  • Cheng Sun
Letter to the Editor

Dear Editor,

Cognitive impairment is a hallmark of neurodegenerative disorders such as Alzheimer’s disease (AD) and Parkinson’s disease. Growing evidence has demonstrated that cognitive impairment is closely associated with insulin resistance. For instance, the risk of AD is increased in diabetic patients [1]. Moreover, cognitively impaired persons exhibit high levels of fasting glucose and fasting insulin, elevated Homeostasis Model Assessment, an impaired insulin response to glucose, and increased frequency of diabetes. In accord with this, intranasal insulin administration greatly improves the delayed memory and caregiver-rated functional ability of patients with amnestic mild cognitive impairment or AD [2].

Cystatin C (CysC) is a ubiquitously-expressed protein and an inhibitor of cysteine protease. It has been demonstrated that plasma CysC is a positive indicator of central adiposity and insulin resistance [3]. Recently, a clinical survey indicated that a higher titer of plasma...



This work was supported by the National Natural Science Foundation of China (81471037 and 81770841); the “Six Kinds of Talents Summit” of Jiangsu Province, China (SWYY-051); Basic Research Program of Education Department of Jiangsu Province, China (14KJA180006); the Program for New Technology of Clinical Diagnosis and Treatment at Nantong (MS22016024); Priority Academic Development Program of Jiangsu Higher Education Institutions.

Compliance with Ethical Standards

Conflict of interest

All authors claim that there are no conflicts of interest.

Supplementary material

12264_2018_226_MOESM1_ESM.pdf (149 kb)
Supplementary material 1 (PDF 149 kb)


  1. 1.
    Cheng D, Noble J, Tang MX, Schupf N, Mayeux R, Luchsinger JA. Type 2 diabetes and late-onset Alzheimer’s disease. Dement Geriatr Cogn Disord 2011, 31: 424–430.CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Craft S, Baker LD, Montine TJ, Minoshima S, Watson GS, Claxton A, et al. Intranasal insulin therapy for Alzheimer disease and amnestic mild cognitive impairment: a pilot clinical trial. Arch Neurol 2012, 69: 29–38.CrossRefPubMedGoogle Scholar
  3. 3.
    Shankar A, Teppala S. Relationship between body mass index and high cystatin levels among US adults. J Clin Hypertens (Greenwich) 2011, 13: 925–930.CrossRefGoogle Scholar
  4. 4.
    Uruska A, Araszkiewicz A, Zozulinska-Ziolkiewicz D, Wegner M, Grzelka A, Wierusz-Wysocka B. Does serum cystatin C level reflect insulin resistance in patients with type 1 diabetes? Clin Biochem 2014, 47: 1235–1238.CrossRefPubMedGoogle Scholar
  5. 5.
    Ji X, Yao L, Wang M, Liu X, Peng S, Li K, et al. Cystatin C attenuates insulin signaling transduction by promoting endoplasmic reticulum stress in hepatocytes. FEBS Lett 2015, 589: 3938–3944.CrossRefPubMedGoogle Scholar
  6. 6.
    Emanuelli B, Peraldi P, Filloux C, Chavey C, Freidinger K, Hilton DJ, et al. SOCS-3 inhibits insulin signaling and is up-regulated in response to tumor necrosis factor-alpha in the adipose tissue of obese mice. J Biol Chem 2001, 276: 47944–47949.CrossRefPubMedGoogle Scholar
  7. 7.
    Yasuhara O, Hanai K, Ohkubo I, Sasaki M, McGeer PL, Kimura H. Expression of cystatin C in rat, monkey and human brains. Brain Res 1993, 628: 85–92.CrossRefPubMedGoogle Scholar
  8. 8.
    Hakansson K, Huh C, Grubb A, Karlsson S, Abrahamson M. Mouse and rat cystatin C: Escherichia coli production, characterization and tissue distribution. Comp Biochem Physiol B Biochem Mol Biol 1996, 114: 303–311.CrossRefPubMedGoogle Scholar
  9. 9.
    Grubb A. Diagnostic value of analysis of cystatin C and protein HC in biological fluids. Clin Nephrol 1992, 38 Suppl 1: S20–27.PubMedGoogle Scholar
  10. 10.
    Shlipak MG, Sarnak MJ, Katz R, Fried LF, Seliger SL, Newman AB, et al. Cystatin C and the risk of death and cardiovascular events among elderly persons. N Engl J Med 2005, 352: 2049–2060.CrossRefPubMedGoogle Scholar
  11. 11.
    Gauthier S, Kaur G, Mi W, Tizon B, Levy E. Protective mechanisms by cystatin C in neurodegenerative diseases. Front Biosci (Schol Ed) 2011, 3: 541–554.Google Scholar
  12. 12.
    Ueki K, Kondo T, Kahn CR. Suppressor of cytokine signaling 1 (SOCS-1) and SOCS-3 cause insulin resistance through inhibition of tyrosine phosphorylation of insulin receptor substrate proteins by discrete mechanisms. Mol Cell Biol 2004, 24: 5434–5446.CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Sarnak MJ, Katz R, Fried LF, Siscovick D, Kestenbaum B, Seliger S, et al. Cystatin C and aging success. Arch Intern Med 2008, 168: 147–153.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Shanghai Institutes for Biological Sciences, CAS and Springer Nature Singapore Pte Ltd. 2018

Authors and Affiliations

  • Lan Luo
    • 1
  • Jinyu Ma
    • 2
  • Yue Li
    • 3
  • Zongkang Hu
    • 3
  • Chengfeng Jiang
    • 3
  • Hao Cai
    • 3
  • Cheng Sun
    • 2
  1. 1.Department of GeriatricsAffiliated Hospital of Nantong UniversityNantongChina
  2. 2.Co-innovation Center of Neuroregeneration, Key Laboratory for Neuroregeneration of Jiangsu Province and the Ministry of EducationNantong UniversityNantongChina
  3. 3.School of MedicineNantong UniversityNantongChina

Personalised recommendations